Urinary 11-dehydro-thromboxane B2 and coagulation activation markers measured within 24 h of human acute ischemic stroke

Joseph P. McConnell, Lynn A. Cheryk, André Durocher, Askiel Bruno, Nils U. Bang, James D. Fleck, Linda Williams, José Biller, James F Meschia

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The aim of this study was to determine the extent of change in platelet and coagulation markers in the acute phase of ischemic stroke and to assess the utility of marker measurement in stroke subtype classification. Urinary 11-dehydro-thromboxane B2 (11-dTXB2), a marker of in vivo platelet activation, and markers of coagulation activation, including prothrombin fragment 1 + 2 (F1 + 2), thrombin-antithrombin complex (TAT), and fibrinogen, were measured in 25 patients with ischemic stroke within 24 h of onset of symptoms. Marker levels in patients with ischemic stroke were compared with those in 19 age-matched controls who had not taken aspirin for at least 2 weeks before sampling and 25 healthy controls. Median marker levels were significantly increased in stroke over those in age-matched controls for fibrinogen (344 vs. 289 mg/dl; P = 0.030), F1 + 2 (1.40 vs. 0.80 nmol/l; P = 0.003), and TAT (6.65 vs. 2.20 μg/l; P < 0.0001). Median marker levels for seven patients with cardioembolic stroke and 18 with non-cardioembolic stroke were not significantly different for any marker test. Eight patients taking aspirin at the time of the stroke had significantly lower 11-dTXB2 values than patients not taking aspirin (964 vs. 4,314 pg/mg of creatinine; P = 0.007). Stroke patients not taking aspirin had significantly higher 11-dTXB2 concentration than age-matched controls (4,314 vs. 1,788 pg/mg of creatinine; P = 0.006). Coagulation and platelet activation markers are increased in the acute phase of stroke regardless of the clinical mechanism. This finding suggests that the markers may not be useful for predicting clinical subtype of ischemic stroke in the acute phase.

Original languageEnglish (US)
Pages (from-to)88-92
Number of pages5
JournalNeuroscience Letters
Volume313
Issue number1-2
DOIs
StatePublished - Nov 2 2001

Fingerprint

Stroke
Aspirin
Platelet Activation
Fibrinogen
Creatinine
11-dehydro-thromboxane B2
Blood Platelets

Keywords

  • 11-Dehydro-thromboxane B
  • Aspirin
  • Cardioembolism
  • Cerebral infarction
  • Coagulation
  • Fibrinogen
  • Platelet activation
  • Thrombin-antithrombin complex

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Urinary 11-dehydro-thromboxane B2 and coagulation activation markers measured within 24 h of human acute ischemic stroke. / McConnell, Joseph P.; Cheryk, Lynn A.; Durocher, André; Bruno, Askiel; Bang, Nils U.; Fleck, James D.; Williams, Linda; Biller, José; Meschia, James F.

In: Neuroscience Letters, Vol. 313, No. 1-2, 02.11.2001, p. 88-92.

Research output: Contribution to journalArticle

McConnell, JP, Cheryk, LA, Durocher, A, Bruno, A, Bang, NU, Fleck, JD, Williams, L, Biller, J & Meschia, JF 2001, 'Urinary 11-dehydro-thromboxane B2 and coagulation activation markers measured within 24 h of human acute ischemic stroke', Neuroscience Letters, vol. 313, no. 1-2, pp. 88-92. https://doi.org/10.1016/S0304-3940(01)02260-1
McConnell, Joseph P. ; Cheryk, Lynn A. ; Durocher, André ; Bruno, Askiel ; Bang, Nils U. ; Fleck, James D. ; Williams, Linda ; Biller, José ; Meschia, James F. / Urinary 11-dehydro-thromboxane B2 and coagulation activation markers measured within 24 h of human acute ischemic stroke. In: Neuroscience Letters. 2001 ; Vol. 313, No. 1-2. pp. 88-92.
@article{bc02f118cafc4a88be59d4d1271ee798,
title = "Urinary 11-dehydro-thromboxane B2 and coagulation activation markers measured within 24 h of human acute ischemic stroke",
abstract = "The aim of this study was to determine the extent of change in platelet and coagulation markers in the acute phase of ischemic stroke and to assess the utility of marker measurement in stroke subtype classification. Urinary 11-dehydro-thromboxane B2 (11-dTXB2), a marker of in vivo platelet activation, and markers of coagulation activation, including prothrombin fragment 1 + 2 (F1 + 2), thrombin-antithrombin complex (TAT), and fibrinogen, were measured in 25 patients with ischemic stroke within 24 h of onset of symptoms. Marker levels in patients with ischemic stroke were compared with those in 19 age-matched controls who had not taken aspirin for at least 2 weeks before sampling and 25 healthy controls. Median marker levels were significantly increased in stroke over those in age-matched controls for fibrinogen (344 vs. 289 mg/dl; P = 0.030), F1 + 2 (1.40 vs. 0.80 nmol/l; P = 0.003), and TAT (6.65 vs. 2.20 μg/l; P < 0.0001). Median marker levels for seven patients with cardioembolic stroke and 18 with non-cardioembolic stroke were not significantly different for any marker test. Eight patients taking aspirin at the time of the stroke had significantly lower 11-dTXB2 values than patients not taking aspirin (964 vs. 4,314 pg/mg of creatinine; P = 0.007). Stroke patients not taking aspirin had significantly higher 11-dTXB2 concentration than age-matched controls (4,314 vs. 1,788 pg/mg of creatinine; P = 0.006). Coagulation and platelet activation markers are increased in the acute phase of stroke regardless of the clinical mechanism. This finding suggests that the markers may not be useful for predicting clinical subtype of ischemic stroke in the acute phase.",
keywords = "11-Dehydro-thromboxane B, Aspirin, Cardioembolism, Cerebral infarction, Coagulation, Fibrinogen, Platelet activation, Thrombin-antithrombin complex",
author = "McConnell, {Joseph P.} and Cheryk, {Lynn A.} and Andr{\'e} Durocher and Askiel Bruno and Bang, {Nils U.} and Fleck, {James D.} and Linda Williams and Jos{\'e} Biller and Meschia, {James F}",
year = "2001",
month = "11",
day = "2",
doi = "10.1016/S0304-3940(01)02260-1",
language = "English (US)",
volume = "313",
pages = "88--92",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

TY - JOUR

T1 - Urinary 11-dehydro-thromboxane B2 and coagulation activation markers measured within 24 h of human acute ischemic stroke

AU - McConnell, Joseph P.

AU - Cheryk, Lynn A.

AU - Durocher, André

AU - Bruno, Askiel

AU - Bang, Nils U.

AU - Fleck, James D.

AU - Williams, Linda

AU - Biller, José

AU - Meschia, James F

PY - 2001/11/2

Y1 - 2001/11/2

N2 - The aim of this study was to determine the extent of change in platelet and coagulation markers in the acute phase of ischemic stroke and to assess the utility of marker measurement in stroke subtype classification. Urinary 11-dehydro-thromboxane B2 (11-dTXB2), a marker of in vivo platelet activation, and markers of coagulation activation, including prothrombin fragment 1 + 2 (F1 + 2), thrombin-antithrombin complex (TAT), and fibrinogen, were measured in 25 patients with ischemic stroke within 24 h of onset of symptoms. Marker levels in patients with ischemic stroke were compared with those in 19 age-matched controls who had not taken aspirin for at least 2 weeks before sampling and 25 healthy controls. Median marker levels were significantly increased in stroke over those in age-matched controls for fibrinogen (344 vs. 289 mg/dl; P = 0.030), F1 + 2 (1.40 vs. 0.80 nmol/l; P = 0.003), and TAT (6.65 vs. 2.20 μg/l; P < 0.0001). Median marker levels for seven patients with cardioembolic stroke and 18 with non-cardioembolic stroke were not significantly different for any marker test. Eight patients taking aspirin at the time of the stroke had significantly lower 11-dTXB2 values than patients not taking aspirin (964 vs. 4,314 pg/mg of creatinine; P = 0.007). Stroke patients not taking aspirin had significantly higher 11-dTXB2 concentration than age-matched controls (4,314 vs. 1,788 pg/mg of creatinine; P = 0.006). Coagulation and platelet activation markers are increased in the acute phase of stroke regardless of the clinical mechanism. This finding suggests that the markers may not be useful for predicting clinical subtype of ischemic stroke in the acute phase.

AB - The aim of this study was to determine the extent of change in platelet and coagulation markers in the acute phase of ischemic stroke and to assess the utility of marker measurement in stroke subtype classification. Urinary 11-dehydro-thromboxane B2 (11-dTXB2), a marker of in vivo platelet activation, and markers of coagulation activation, including prothrombin fragment 1 + 2 (F1 + 2), thrombin-antithrombin complex (TAT), and fibrinogen, were measured in 25 patients with ischemic stroke within 24 h of onset of symptoms. Marker levels in patients with ischemic stroke were compared with those in 19 age-matched controls who had not taken aspirin for at least 2 weeks before sampling and 25 healthy controls. Median marker levels were significantly increased in stroke over those in age-matched controls for fibrinogen (344 vs. 289 mg/dl; P = 0.030), F1 + 2 (1.40 vs. 0.80 nmol/l; P = 0.003), and TAT (6.65 vs. 2.20 μg/l; P < 0.0001). Median marker levels for seven patients with cardioembolic stroke and 18 with non-cardioembolic stroke were not significantly different for any marker test. Eight patients taking aspirin at the time of the stroke had significantly lower 11-dTXB2 values than patients not taking aspirin (964 vs. 4,314 pg/mg of creatinine; P = 0.007). Stroke patients not taking aspirin had significantly higher 11-dTXB2 concentration than age-matched controls (4,314 vs. 1,788 pg/mg of creatinine; P = 0.006). Coagulation and platelet activation markers are increased in the acute phase of stroke regardless of the clinical mechanism. This finding suggests that the markers may not be useful for predicting clinical subtype of ischemic stroke in the acute phase.

KW - 11-Dehydro-thromboxane B

KW - Aspirin

KW - Cardioembolism

KW - Cerebral infarction

KW - Coagulation

KW - Fibrinogen

KW - Platelet activation

KW - Thrombin-antithrombin complex

UR - http://www.scopus.com/inward/record.url?scp=0035798275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035798275&partnerID=8YFLogxK

U2 - 10.1016/S0304-3940(01)02260-1

DO - 10.1016/S0304-3940(01)02260-1

M3 - Article

VL - 313

SP - 88

EP - 92

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

IS - 1-2

ER -